Brentuximab: is it time for a new "B" in ABVD?
- PMID: 28912294
- DOI: 10.1182/blood-2017-08-798553
Brentuximab: is it time for a new "B" in ABVD?
Conflict of interest statement
Conflict-of-interest disclosure: The author declares no competing financial interests.
Comment on
-
Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.Blood. 2017 Sep 14;130(11):1375-1377. doi: 10.1182/blood-2017-05-784678. Epub 2017 Jul 21. Blood. 2017. PMID: 28733323 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical